{"filings":[{"id":1417476,"accession_number":"0001005286-26-000026","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-07-02T21:17:29+00:00","items":["7.01"],"status":"ready","headline":"Lifecore Biomedical receives redemption notices for all Series A Preferred Stock; $52.1M due Dec 28, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of all 49,263 Series A Preferred shares (100% outstanding) submitted redemption notices on June 29-30, 2026.","Redemption price $1,000/share plus accrued dividends; total ~$52.1M due Dec 28, 2026.","Company had $38.1M total liquidity as of March 31, 2026 ($20.8M cash, $17.3M revolver availability).","Company must obtain lender consent to pay redemption; otherwise 1% monthly interest on unpaid balance.","Company evaluating strategic alternatives including debt/equity financing or other transactions to fund redemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888399,"accession_number":"0001005286-26-000023","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-06-05T20:10:37+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Lifecore stockholders approve 2026 equity plan; all director nominees elected at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2026 Stock Incentive Plan (2.5M new shares plus forfeited 2019 Plan shares) effective Oct 16, 2026.","All nine director nominees elected: 7 by all stockholders (Houde, Antunes, Johnson, Josephs, Korenberg, Obus, Schechter); 2 by Series A preferred (Aryeh, Kiper).","Ratified KPMG as auditor (33.8M for); approved non-binding say-on-pay (22.9M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90546,"accession_number":"0001005286-26-000018","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.","Net loss $15.0M ($0.43 loss per diluted share) vs $14.8M loss year ago.","Adjusted EBITDA $1.0M, down $4.7M from $5.7M; operating expenses cut 52%.","Signed three new commercial site transfer programs in Q1; reaffirms full-year 2026 guidance.","Liquidity $38.1M (cash $20.8M, revolver $17.3M); free cash flow $3.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":23193000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100150,"accession_number":"0001005286-26-000007","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.","Net loss for transition period $18.0M, improved from $30.6M; Adjusted EBITDA $13.1M, up from $2.6M.","Gross margin 31% vs 26%; operating expenses decreased 31% to $24.4M.","Signed five new programs during transition, including two commercial site transfer programs in Q4.","Liquidity of $38.9M at quarter end; mid-term target: 12% revenue CAGR, EBITDA margins >25%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100149,"accession_number":"0001005286-26-000002","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Lifecore Biomedical fiscal year change to calendar; 2026 annual meeting June 4, proposals due March 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board changed fiscal year from May-ending to calendar year, effective May 26, 2025 – Dec 31, 2025.","2026 Annual Meeting set for June 4, 2026, more than 30 days from prior Oct 29, 2025 meeting.","Deadline for shareholder proposals/nominations under Rule 14a-8 or otherwise is March 16, 2026.","Proposals must comply with SEC rules, Bylaws, and Delaware law; send to Chaska, MN address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100148,"accession_number":"0001628280-26-002400","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lifecore Biomedical adopts Incentive Bonus Plan for executives and key employees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Plan effective Jan 14, 2026; covers executive officers and selected employees.","Bonus payments based on achievement of financial/operational/strategic targets set by Compensation Committee.","Committee has discretion over participants, targets, weights, and adjustments for unusual events.","Includes clawback via existing Recoupment Policy adopted Nov 30, 2023.","No specific bonus targets or amounts disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116482,"accession_number":"0001005286-25-000150","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lifecore changes fiscal year to calendar year, effective May 26, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved fiscal year change on Aug 1, 2025; new calendar year ends Dec 31.","Transition period of ~7 months from May 26, 2025 to Dec 31, 2025.","Prior fiscal year ended May 25, 2025 (FY2025); prior periods not adjusted.","Presentation used at Jefferies Healthcare Conference in November 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116481,"accession_number":"0001005286-25-000146","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.","Net loss narrowed to $10.0M ($0.29 loss per share) from $16.2M ($0.53) a year ago.","Adjusted EBITDA of $3.1M vs negative $1.8M in prior year; SG&A down $5.9M.","Affirms transition period guidance: revenue $74-76M, Adjusted EBITDA $12-14M.","Signed 4 new programs (2 post-quarter); commercial site transfer with large pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":31109000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116480,"accession_number":"0001005286-25-000138","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lifecore Biomedical stockholders elect nine directors and ratify KPMG at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Katrina L. Houde, Humberto C. Antunes, Paul H. Johnson, Paul Josephs, Matthew E. Korenberg, Nelson Obus, Joshua E. Schechter elected by common and Series A holders.","Series A preferred stockholders elected Jason Aryeh and Christopher S. Kiper as directors with 38,776 votes for each.","Ratification of KPMG LLP as independent auditor for fiscal 2025 received 35,663,643 votes for, 15,326 against.","Non-binding advisory vote on named executive officer compensation approved with 24,642,130 votes for, 238,354 against.","A total of 37,436,784 common shares and 46,593 Series A preferred shares were outstanding on the record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132939,"accession_number":"0001005286-25-000133","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifecore Biomedical approves CY 2025 transition bonus plan; CEO target 100% of base salary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New bonus plan covers the approximate seven-month transition period May 26, 2025 through Dec 31, 2025.","Bonus weighted 80% on Adjusted EBITDA and total revenue, 10% on individual objectives, 10% on company goals.","Target bonus as % of transition-period base salary: CEO Paul Josephs 100%, CFO Ryan Lake 60%, Chief Legal Tom Salus 50%.","Maximum payout capped at 200% of target level for financial goals; minimum Adjusted EBITDA threshold applies.","CY 2025 plan replaces the prior FY 2026 Bonus Plan terminated due to the fiscal year change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132938,"accession_number":"0001005286-25-000118","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Lifecore Biomedical dismisses BDO and appoints KPMG as new independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved appointment of KPMG on August 12, 2025 as independent registered public accounting firm for transition period ending December 31, 2025.","BDO was dismissed on August 12, 2025; its audit reports for fiscal years ended May 26, 2024 and May 25, 2025 did not contain adverse opinions.","BDO's reports stated internal control material weaknesses existed as of May 26, 2024 and May 25, 2025 based on COSO criteria.","No disagreements or reportable events occurred between Lifecore and BDO during the covered periods.","Material weaknesses included deficiencies in control environment, risk assessment, and monitoring as previously disclosed in the Annual Report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132937,"accession_number":"0001005286-25-000115","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical files investor presentation under Regulation FD; no material updates visible in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing furnishes a presentation dated August 12, 2025 for investor discussions.","No specific financial results, guidance, or material events disclosed in the filing body.","Full presentation content not included in provided text, limiting assessable news."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132936,"accession_number":"0001005286-25-000106","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.","FY2025 revenue $128.9M (+0.5% YoY); net loss $38.7M vs $12.0M income; adj. EBITDA $19.5M vs $20.2M.","Signed nine new customer programs in FY2025; post-quarter added GLP-1 obesity therapy and Phase 2 dermatology programs.","Transition period (May-Dec 2025) guidance: revenue $74-76M; adj. EBITDA $12-14M; net loss $19.8-17.8M.","Moving fiscal year to calendar year-end Dec 31, 2025; new ERP system planned for Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":8665000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132935,"accession_number":"0001005286-25-000097","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifecore Biomedical approves FY2026 bonus plan for executives with EBITDA, revenue targets","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved FY2026 cash bonus plan for CEO Paul Josephs (100% target), CFO Ryan Lake (60%), and CAO Thomas Salus (50%).","Bonus weighted 80% to Adjusted EBITDA and development revenue; max payout 200% of target; no bonus if minimum EBITDA unmet.","Individual performance goals and company business goals each weighted 10%.","Salus receives 125% of any bonus earned per employment agreement; all bonuses subject to clawback policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149481,"accession_number":"0001005286-25-000072","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lifecore Biomedical increases Equity Inducement Plan by 750,000 shares to 4,250,000 total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board of Directors amended the Equity Inducement Plan on April 11, 2025, adding 750,000 shares.","Total shares reserved for awards under the Plan increased to 4,250,000.","Shares may be issued as incentive stock options from authorized but unissued or treasury shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149480,"accession_number":"0001005286-25-000061","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lifecore Biomedical shareholders approve issuance of shares beyond 19.99% threshold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At April 10, 2025 special meeting, stockholders approved the Issuance Proposal, allowing issuance of common stock underlying Series A Preferred Stock in excess of 19.99% of outstanding common shares.","Votes on Issuance Proposal: 24,098,218 For, 444,639 Against, 33,281 Abstain.","Adjournment Proposal was also approved (28,882,501 For) but not needed since Issuance Proposal passed.","The approval relates to the Securities Purchase Agreement dated January 9, 2023, with named investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149479,"accession_number":"0001005286-25-000052","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.","Net loss of $14.8M ($0.47 diluted loss per share) vs prior-year net income of $15.6M including $21M non-cash debt derivative gain.","Adjusted EBITDA $5.7M, down from $6.4M YoY; gross profit fell to $9.8M from $11.9M.","Sold unused high-speed isolator filler for $17M; $7M received at closing, remainder over 18 months. Signed multiple new development agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":92423000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168560,"accession_number":"0001005286-25-000028","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lifecore to hold special meeting April 10 to remove Series A preferred conversion cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on April 10, 2025 to vote on removing the 19.99% conversion cap on Series A Convertible Preferred Stock.","If approved, up to 6,056,284 common shares could be issued upon conversion at the current conversion price.","No holders have elected to convert as of Jan 17, 2025; company has no plans to raise additional equity capital.","Board sets record date of Feb 18, 2025 for voting eligibility.","Proposal needed to comply with Nasdaq Listing Rule 5635(d) regarding issuance over 19.99% of outstanding common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168559,"accession_number":"0001005286-25-000014","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lifecore sells excess 10-head isolator filler for $17M; strengthens financial position","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale agreement for 10-head isolator filler with non-competitive buyer; purchase price $17M.","$7M received at closing; remaining payments in three tranches over the next 18 months.","Newly installed 5-head filler provides $300M in annual revenue capacity.","Sale reflects ongoing right-sizing and efficiency review; management cites alignment with growth objectives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168558,"accession_number":"0001005286-25-000009","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Q2 FY25 revenue up 8% to $32.6M; net loss $6.6M on non-cash items; adj EBITDA $6.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $32.6M (+8% YoY); CDMO segment drove $1.9M increase, partially offset by customer mix shifts.","Net loss of $6.6M ($0.25 diluted loss) vs prior-year net income of $14.2M which included a $20.7M non-cash gain.","Adjusted EBITDA $6.5M, up from $5.4M YoY, driven by higher gross profit from pricing and mix.","Completed $24.3M equity private placement and amended BMO credit facility with lower rates and 3-year extension.","Signed new CDMO project with Nirsum Labs; installed GMP-ready 5-head isolator filler, doubling capacity to ~$300M annual revenue potential."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":62956000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185668,"accession_number":"0001005286-24-000169","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lifecore extends BMO revolving credit facility to Nov 2027, lowers rates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended three years to November 2027 under BMO ABL facility.","Interest rates simplified and reduced; no fees paid for amendments.","Alcon term loan covenants aligned with BMO facility via separate amendment.","Follows $24.3M PIPE financing; company says balance sheet strengthened.","CEO cites BMO confidence and recent customer wins including Lindy Biosciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185667,"accession_number":"0001005286-24-000166","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical hosts Investor Day; presentation signals new strategic era","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Lifecore Biomedical hosted an Investor Day on November 21, 2024, releasing a presentation.","Presentation titled 'A New Era: Building Momentum for Sustainable Growth' suggests strategic narrative shift.","No specific financial targets, operational milestones, or strategic actions disclosed in the provided excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185666,"accession_number":"0001005286-24-000163","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lifecore Biomedical annual meeting elects five directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Matthew Korenberg, Humberto Antunes, Nelson Obus, Katrina Houde elected by common and preferred holders voting together; Christopher Kiper elected solely by preferred holders.","Nelson Obus received 2,115,224 votes against, the highest among common stock directors; rest received fewer than 200,000 against.","Ratification of BDO USA as auditor for FY2025 passed with 31,279,291 for, 29,609 against, 38,781 abstain.","Advisory vote on executive compensation approved with 23,645,284 for, 163,003 against, 41,099 abstain; broker non-votes 7,498,295.","Total shares of common stock outstanding and entitled to vote at record date: 36,855,072; Series A Preferred on as-converted basis: 5,889,404."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185665,"accession_number":"0001005286-24-000144","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Lifecore raises $24.3M via stock sale; Q1 net loss widens to $16.2M, reaffirms FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sold 5,928,775 shares at $4.10 for gross proceeds of $24.3M to investors including Legion Partners, Greenhaven, Wynnefield, 325 Capital.","Q1 FY25 revenue $24.7M (flat YoY); net loss $16.2M ($0.53 per share) vs $10.8M loss prior year.","Adjusted EBITDA $(1.8)M in line with prior year $(2.0)M; FY25 guidance reaffirmed: rev $126.5-130M, Adj EBITDA $19-21M.","Installed 5-head isolator filler doubling capacity to $300M revenue potential; signed four new customers including Lindy Biosciences.","Regained Nasdaq compliance; added two sales reps; plans Investor Day in November to detail medium-term targets."],"consensus_eps_estimate":-0.153,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":24705000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202243,"accession_number":"0001005286-24-000138","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02","5.08"],"status":"ready","headline":"Lifecore Biomedical announces two director departures, Nov 7 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey L. Edwards will not stand for re-election; Ray Diradoorian resigns effective before 2024 annual meeting.","Both directors said their decisions were not due to any disagreement with the company.","Annual meeting set for November 7, 2024; shareholder proposals due by October 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202242,"accession_number":"0001005286-24-000130","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lifecore Biomedical regains Nasdaq compliance, avoids delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed overdue Q3 FY2023 and Q1/Q2 FY2024 10-Qs on Aug 8, 2024, and FY2024 10-K on Aug 26, 2024.","Held 2024 annual meeting on Aug 15, 2024, curing Annual Meeting Rule deficiency.","Nasdaq will monitor compliance until Sept 4, 2025; further failure to file timely could lead to delisting without cure period.","Company's common stock remains listed on The Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202241,"accession_number":"0001005286-24-000128","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["3.02","5.02","7.01","9.01"],"status":"ready","headline":"Lifecore appoints Ryan Lake as CFO effective Sept 3; Morberg departs Sept 2","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Morberg steps down as CFO effective Sept 2, 2024; Ryan Lake succeeds him on Sept 3, 2024.","Lake receives $470K base salary, RSU for 262,500 shares, and PSU for up to 750,000 shares under Inducement Plan.","Lake previously served as CFO of Societal CDMO, leading its sale to CoreRx in April 2024.","Morberg's separation treated as termination without Cause after a Change in Control under his employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202240,"accession_number":"0001005286-24-000125","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifecore reports FY 2024 revenue $128.3M (+24.2%), Adj. EBITDA $20.2M; FY25 rev guidance $126.5-130M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 revenue $128.3M (+24.2% YoY); Q4 revenue $37.9M (+21.6% YoY).","FY 2024 net income $9.3M (incl. $39.5M non-cash gain) vs loss $64.2M; Adj. EBITDA $20.2M.","Q4 net loss $7.1M vs $37.0M (prior yr had $23.7M debt extinguish loss); Adj. EBITDA $10.4M.","FY 2025 guidance: rev $126.5-130M, Adj. EBITDA $19-21M, capex $10-14M.","5-head isolator filler GMP-ready Sept 2024; headcount reduced in July; SEC filings current."],"consensus_eps_estimate":-0.153,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":24705000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202239,"accession_number":"0001005286-24-000119","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["3.03","5.02","5.03","5.07","9.01"],"status":"ready","headline":"Lifecore shareholders approve board declassification, share increase; appoints four new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved phased-in board declassification: 21.6M for, 77K against.","Authorized common shares increased to 75M from 50M.","Four new directors appointed: Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, Matthew Korenberg.","Director Nathaniel Calloway resigned post-meeting; no disagreement cited.","2019 Stock Incentive Plan amended: +300K shares available, total 3,059,797 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202238,"accession_number":"0001005286-24-000093","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifecore Biomedical approves FY2025 Annual Incentive Plan with EBITDA-based bonuses","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Paul Josephs target bonus 100% of base salary; CFO John D. Morberg 60%.","Plan weighted 80% on Adjusted EBITDA and 20% on four business objectives.","Maximum payout capped at 200% of target; minimum EBITDA threshold required.","Clawback provision under Compensation Recoupment Policy applies to all payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202237,"accession_number":"0001005286-24-000086","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Lifecore Biomedical cuts 46 jobs (9% of workforce); expects $1.0M in severance costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce Reduction Plan eliminates 46 full-time employees, approximately 9% of total workforce.","Estimated termination benefit costs of ~$1.0 million, primarily one-time severance.","Costs to be incurred in Q1 FY2025 and paid during Q1 and Q2 of fiscal 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202236,"accession_number":"0001005286-24-000081","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Lifecore settles proxy fight with 22NW, adds four new directors and declassification proposal","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["22NW withdraws director nominations and special meeting demand; board declassification proposal at 2023 annual meeting.","Four new directors appointed: Humberto Antunes, Jason Aryeh, Paul Johnson, Matthew Korenberg.","Standstill agreements with 22NW, Legion, Wynnefield through 2025 annual meeting.","Board size to reduce to 8 pre-AGM, expand to 11 post-AGM, then back to 9 by Nov 2024.","Three investor groups collectively own ~43.5% of voting securities on as-converted basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218324,"accession_number":"0001005286-24-000077","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lifecore receives Nasdaq delisting notice for missing annual meeting and filing delays","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Lifecore on June 3, 2024 of non-compliance with listing rules.","Failure to hold 2023 annual meeting within 12 months of fiscal year-end (May 28, 2023) triggered Rule 5620(a).","Delays in filing Q1, Q2, and Q3 FY2024 Forms 10-Q violate Rules 5810(c)(2)(G) and 5250(c)(1).","Company has scheduled 2023 annual meeting for August 15, 2024 and will request extension from Nasdaq Hearings Panel.","Nasdaq previously granted stay; delisting decision is pending; no immediate effect on stock trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218323,"accession_number":"0001005286-24-000071","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Lifecore CEO James Hall resigns; Paul Josephs appointed CEO and director effective May 20","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James G. Hall resigned as director, President and CEO effective May 19, 2024.","Paul Josephs appointed President, CEO and director effective May 20, 2024.","Josephs previously CEO of Woodstock Sterile Solutions (CDMO) from April 2021 to May 2024.","Granted 525,000 RSUs (25k vested immediately, 100k/year over 5 years) and up to 1.5M PSUs with performance price targets from $7.50 to $35.00 per share.","Josephs enters Tier 1 Change in Control Severance Plan benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218322,"accession_number":"0001005286-24-000067","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lifecore adds ~$8M non-dilutive liquidity via lender amendments; assigns Curation Foods assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$5.5M prepayment from term lender as advance on future purchases; lender can apply to invoices in 2026.","FILO amendment adds ~$2.5M incremental revolver capacity under ABL; margin SOFR+4.25%, annual interest +~$44k.","Assignment for benefit of creditors of wholly owned subsidiary Curation Foods to SG Service Co. for liquidation.","Pro forma cash post-initiatives would be $11.0M (up from $3.0M); total debt $178.9M.","2024 Annual Incentive Plan amended: CEO & CFO cash incentives to be paid in unrestricted common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218321,"accession_number":"0001005286-24-000062","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Lifecore amends ABL facility with FILO tranche; still faces Nasdaq delisting risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered FILO tranche under ABL credit agreement with BMO; FILO loans bear SOFR +4.25%.","Nasdaq Panel requested additional info on delayed filings; company responded May 10 and 14, 2024; no decision yet.","Company continues to work to file delinquent periodic reports to regain Nasdaq Listing Rule 5250(c)(1) compliance.","Repayments apply first to non-FILO, then FILO loans; FILO cap reduces monthly from October 2025.","Seventh Amendment effective May 10, 2024; Loan Parties reaffirm obligations and release claims against lenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218320,"accession_number":"0001005286-24-000059","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["1.01","5.08","9.01"],"status":"ready","headline":"Lifecore gets $5.5M prepayment from Alcon; annual meeting set for Aug 15, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alcon Research paid $5.5M prepayment for future product purchases; credits apply in 2026.","Lifecore subsidiary amends contract manufacturing agreement with Alcon, effective May 2, 2024.","Board sets 2023 annual meeting for Aug 15, 2024; shareholder proposals due by May 18, 2024.","Prepayment provides $5.5M near-term liquidity; customer commitment indicator."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218319,"accession_number":"0001005286-24-000056","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifecore changes executive incentive from cash to stock for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO John D. Morberg and James G. Hall will receive FY2024 incentive in fully vested, unrestricted shares instead of cash.","Number of Bonus Shares equals cash incentive amount divided by fair market value on determination date.","Shares issued under 2019 Stock Incentive Plan; if insufficient reserves, pro rata issuance with contingent shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218318,"accession_number":"0001005286-24-000054","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Lifecore Biomedical appoints BDO USA as independent auditor for FY 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee approved BDO USA as independent auditor effective April 29, 2024 for fiscal year ending May 26, 2024.","No prior consultations with BDO on accounting principles or audit opinions were conducted.","No disagreements or reportable events with predecessor auditor were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218317,"accession_number":"0001005286-24-000050","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Lifecore receives Nasdaq notice for delayed Q3 10-Q; hearing held April 16, decision pending","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on April 15, 2024, cites continued non-compliance with Listing Rule 5250(c)(1) due to late Q3 10-Q and prior Q1/Q2 filings.","Company appealed prior Staff Delisting Determination; hearing held April 16, 2024, requesting further stay of suspension/delisting.","Nasdaq Hearings Panel has not yet issued a decision; no immediate effect on LFCR stock trading.","Company intends to file overdue reports as promptly as possible but gives no assurance of timeline or panel grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218316,"accession_number":"0001005286-24-000041","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifecore provides FY2024 guidance: rev $125M-$130M; 9M rev $90.5M (+25% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Nine-month revenue through Feb 24, 2024: $90.5M vs restated $72.1M in prior year, up 26%.","Full-year FY2024 guidance: revenue $125M-$130M, adjusted EBITDA $13.5M-$16.9M.","Development portfolio grows to 33 projects (+4 YoY); prospective pipeline has 68 opportunities.","Capacity expansion: theoretical capacity to triple to ~70M units by FY2027; 5-head filler GMP-ready Aug 2024.","Alcon HA supply agreement: capacity up 38% in FY2024; further 20% yield improvement expected in FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":90375000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238265,"accession_number":"0001005286-24-000039","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"EY declines reappointment as Lifecore auditor; cites material weaknesses in internal controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ernst & Young notified Lifecore on March 20, 2024 it will not stand for reappointment as auditor for FY ending May 26, 2024.","EY issued adverse opinions on internal controls for FY2023 and FY2022 due to material weaknesses.","EY's FY2022 audit report included a going-concern explanatory paragraph.","No accounting disagreements; company is actively seeking a new independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238264,"accession_number":"0001005286-24-000036","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Lifecore appoints Paul Josephs as CEO; concludes strategic review, remains standalone","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Josephs becomes President & CEO effective May 20, 2024, succeeding James Hall, who retires after 30+ years.","Strategic review with 75+ buyers concluded; Board unanimously chose standalone execution.","Josephs receives $550k base salary, 525k RSU (vest over 5 yrs), up to 1.5M PSU shares tied to stock price.","Hall separation: $750k severance over 12 months, full equity vesting, COBRA premiums for 12 months.","Craig Barbarosh not standing for reelection; Katrina Houde to become Board Chair at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238263,"accession_number":"0001005286-24-000033","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifecore files FY23 10-K with restatements for FY21-22; corrects inventory and interest errors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed FY23 Annual Report on Form 10-K with SEC on March 20, 2024, restating FY22, FY21, and multiple quarterly periods.","Restatements correct errors in capitalized interest, inventory valuation (write-downs to net realizable value), and excess/obsolete reserves.","Lifecore segment adjustments include gross-up of revenues for principal arrangements and accounts receivable reserve for a specific customer.","Curation Foods segment restatements involve non-current other receivables and reclassification of operating costs between continuing and discontinued ops.","Company furnished supplementary summary of select financial data on its website to assist investor analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238262,"accession_number":"0001005286-24-000020","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Lifecore receives Nasdaq delisting notice for failure to file FY 2023 10-K and Q1/Q2 10-Qs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq initiated delisting process on Feb 13, 2024 due to non-compliance with Listing Rule 5250(c)(1).","Company has not filed Form 10-K for FY ended May 28, 2023 nor Q1 and Q2 10-Qs for 2023.","Company intends to appeal before a Nasdaq Hearing Panel by Feb 20, 2024; hearing automates 15-day stay.","Hearing typically scheduled 30-45 days after request; no assurance of further stay or compliance before hearing.","Delinquent filings relate to a previously disclosed restatement for FY 2021, 2022 and other interim periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238261,"accession_number":"0001005286-24-000013","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical receives Nasdaq notice for delayed quarterly and annual filings","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Lifecore on Jan 10, 2024 that it is not compliant with Listing Rule 5250(c)(1) due to delayed Q2 Form 10-Q and continued delays in Form 10-K and Q1 Form 10-Q.","The company had a previously approved compliance plan with an exception period until Feb 12, 2024 to file Form 10-K and Q1 Form 10-Q.","Lifecore plans to submit an updated compliance plan by Jan 25, 2024 to address the Q2 Form 10-Q filing and regain compliance.","The notice has no immediate effect on the listing or trading of LFCR common stock on Nasdaq Global Select Market.","The company continues to work to complete the filings but cannot assure regaining compliance by the deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238260,"accession_number":"0001005286-24-000004","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Lifecore expands Alcon CDMO contract through 2031; receives credit waivers on delayed reports","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered 8-year Amended CMA with Alcon through Dec 2031 for aseptic manufacturing of ophthalmic devices.","Alcon gets option to purchase new filter dryer to expand HA capacity; costs paid by Alcon.","Alcon and BMO granted waivers on delayed financial reporting under Term Loan and Revolving Credit agreements.","Strategic alternative review remains ongoing; no timetable or decision set.","Company expects to file overdue 2023 10-K in near-term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255742,"accession_number":"0001005286-23-000122","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DOJ declines prosecution of Lifecore for FCPA violations; $406,505 disgorgement agreed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DOJ declines to prosecute Lifecore for FCPA violations involving former subsidiary Yucatan Foods.","Lifecore to pay disgorgement of $406,505 as part of resolution.","Company to continue cooperating with ongoing government investigations.","Resolution stems from voluntary self-disclosure previously disclosed in public filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255741,"accession_number":"0001005286-23-000118","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Lifecore Biomedical restating FY21, FY22 financials for errors in interest, inventory, and divestitures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee concludes prior financials for FY21, FY22, and interim periods 2020-2023 should no longer be relied upon.","Errors involve capitalized interest calculation, inventory valuation, and adjustments related to former Curation Foods segment.","Material weaknesses in internal control over financial reporting identified as of May 29, 2022.","Restatement expected to impact FY23 earnings release; company expects no adverse effect on operations or liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255740,"accession_number":"0001005286-23-000116","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Lifecore receives Nasdaq delisting notice for delayed filings; compliance plan submitted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 12, 2023 for failure to timely file Form 10-Q (period ended Aug 27, 2023) and still-delinquent Form 10-K (period ended May 28, 2023).","Submitted compliance plan on Oct 16, 2023; if accepted, Nasdaq may grant up to 180 days from Form 10-K due date (Feb 12, 2024) to regain compliance.","No immediate impact on listing or trading of common stock on Nasdaq Global Select Market.","Company states it is working diligently to complete and file the delinquent reports as promptly as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":180795349.17083338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-10-18T23:59:59+00:00|255740"}